The patent will provide important protection for medical for treatment of patients with complete spinal cord injury. A corresponding patent has previously been granted in China and during 2018 in Australia, the U.S., and Japan. BioArctic has an active patent strategy covering all major geographic markets, including the U.S., Japan, China, and Europe.
"The patent protection in Europe is in line with the company's strategy to protect important products through patents. A clinical Phase 1/2 study with the product candidate SC0806 for patients with complete spinal cord injury is currently ongoing. These patients lack effective treatment today. Our ambition is to develop SC0806 and thus improve the patients' quality of life," said Gunilla Osswald, CEO of BioArctic.